Cyproterone acetate (CPA) is an oral anti-androgen commonly used to treat advanced prostate cancer.
A variety of hepatotoxic reactions has been reported with CPA. Here we describe a case of a male patient who developed severe drug-induced hepatotoxicity during the treatment with CPA. The case, presenting sub-acute hepatitis, was characterized by a rapid evolution of cirrhosis and a protracted activity during the period of a few months despite the treatment withdrawal and an apparent benefits of corticosteroids, suggesting their indication in life threatening cases.
Written by:
Abenavoli L, Milic N, Beaugrand M. Are you the author?
Department of Health Sciences, University "Magna Græcia" of Catanzaro, Italy; Service d'Hépato-Gastroentérologie, Hôpital Jean Verdier, Bondy Cedex, France.
Reference: Ann Hepatol. 2013 Jan;12(1):152-5.
PubMed Abstract
PMID: 23293208
Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com
UroToday.com Prostate Cancer Section
